Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.70−0.23 (-2.90%)
Close on Nov 13, 2026Market cap $77.29MP/E –Yield –
Atara Biotherapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Atara Biotherapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$13.53M, down 146.0% year over year. For fiscal 2025 it was $37.98M. The highest annual figure on record is $37.98M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.98M | – |
| FY2024 | Dec 31, 2024 | -$78.39M | – |
| FY2023 | Dec 31, 2023 | -$271.18M | – |
| FY2022 | Dec 31, 2022 | -$274.86M | – |
| FY2021 | Dec 31, 2021 | -$331.12M | – |
| FY2020 | Dec 31, 2020 | -$300.72M | – |
| FY2019 | Dec 31, 2019 | -$288.61M | – |
| FY2018 | Dec 31, 2018 | -$233.38M | – |
| FY2017 | Dec 31, 2017 | -$120.58M | – |
| FY2016 | Dec 31, 2016 | -$80.86M | – |
| FY2015 | Dec 31, 2015 | -$58.40M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.97M | – |
| Q2 FY2026 | Jun 30, 2026 | -$4.71M | -237.1% |
| Q1 FY2026 | Mar 31, 2026 | -$3.34M | -108.2% |
| Q4 FY2025 | Dec 31, 2025 | -$2.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.54M | – |
| Q2 FY2025 | Jun 30, 2025 | $3.43M | – |
| Q1 FY2025 | Mar 31, 2025 | $40.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.10M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$58.76M | – |
| Q3 FY2023 | Sep 30, 2023 | -$68.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$70.21M | – |
| Q1 FY2023 | Mar 31, 2023 | -$73.80M | – |
| Q4 FY2022 | Dec 31, 2022 | -$74.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$83.22M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$86.63M | – |
| Q4 FY2021 | Dec 31, 2021 | -$90.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$82.51M | – |
| Q2 FY2021 | Jun 30, 2021 | -$81.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$76.02M | – |
| Q4 FY2020 | Dec 31, 2020 | -$79.54M | – |
| Q3 FY2020 | Sep 30, 2020 | -$72.51M | – |
| Q2 FY2020 | Jun 30, 2020 | -$75.85M | – |
| Q1 FY2020 | Mar 31, 2020 | -$72.75M | – |
| Q4 FY2019 | Dec 31, 2019 | -$77.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$70.76M | – |
| Q2 FY2019 | Jun 30, 2019 | -$73.74M | – |
| Q1 FY2019 | Mar 31, 2019 | -$66.24M | – |
| Q4 FY2018 | Dec 31, 2018 | -$80.34M | – |
| Q3 FY2018 | Sep 30, 2018 | -$59.02M | – |
| Q2 FY2018 | Jun 30, 2018 | -$51.92M | – |
| Q1 FY2018 | Mar 31, 2018 | -$42.12M | – |
| Q4 FY2017 | Dec 31, 2017 | -$35.52M | – |
| Q3 FY2017 | Sep 30, 2017 | -$31.36M | – |
| Q2 FY2017 | Jun 30, 2017 | -$27.71M | – |
| Q1 FY2017 | Mar 31, 2017 | -$25.96M | – |
| Q4 FY2016 | Dec 31, 2016 | -$18.57M | – |
See a number that looks wrong?